
ORAMED PHARMACEUTICALS INC.
100
Recent developments include leadership changes at Lifeward, Oramed's transfer of POD technology to Lifeward with a significant ownership stake, strategic alliances, and recognition among biotech stocks at 52-week highs.
- Lifeward named Josh Hexter as interim CEO and Rami Aviram as CFO in September 2026 [N1].
- Oramed transferred its POD technology to Lifeward and received a 49.9% beneficial ownership interest in Lifeward in January 2026 [N4].
- Oramed formed a strategic alliance with Alpha Tau following a $36.9 million offering in April 2025 [N5].
- Oramed's new OraTech venture aims to revolutionize diabetes care with oral insulin delivery as of February 2025 [N7].
- Oramed was noted among biotech stocks at 52-week highs in August 2026 [N2].
Oramed Pharmaceuticals Inc. is a pharmaceutical company specializing in oral insulin delivery and related technologies. The company has transitioned its POD technology platform to OraTech, which now conducts related research and development activities. Oramed holds a 49.9% beneficial ownership interest in Lifeward, a medical device company focused on advancing medical technologies. The company also has strategic alliances and investments in clinical-stage companies such as Alpha Tau and Scilex. Oramed's revenue has been primarily derived from license agreements, with recent decreases due to full recognition of deferred revenue and strategic shifts. Financially, Oramed reported net income and maintains strong liquidity with a current ratio above 6 as of September 30, 2026. The company faces risks related to joint ventures, healthcare policy reforms, currency exchange exposure, and the performance of its investments. Oramed's common stock is listed on the Nasdaq Capital Market and subject to listing requirements and market volatility [S1][S2][N4][N5][N7].
Financial figures (if any) are summarized from the latest available SEC filings and are provided for informational purposes only — not financial advice. Oramed Pharmaceuticals Inc. focuses on oral insulin delivery technology and related pharmaceutical ventures. The company transferred its POD technology platform to OraTech in early 2026 and holds a significant ownership stake in Lifeward, a medical device company. Oramed also maintains strategic investments in Alpha Tau and Scilex, with financial income largely reflecting unrealized gains and losses on these investments. The company reported a net income of approximately $13.5 million for the nine months ended September 30, 2026, with strong liquidity ratios and a current ratio of 6.07. Research and development expenses decreased due to the transfer of technology activities, while general and administrative expenses increased primarily due to stock-based compensation. Risks include joint venture limitations, healthcare policy changes, currency fluctuations, and investment risks in associated companies [S1][S2].
Oramed's strategic transfer of its POD technology to OraTech and its substantial ownership interest in Lifeward position it to benefit from advancements in oral insulin delivery and medical device innovation. The company's alliance with Alpha Tau and other investments provide exposure to promising clinical-stage therapeutics. Strong liquidity and recent net income reflect financial stability to support ongoing operations and strategic initiatives. The recognition of license revenues and gains from investment revaluations contribute to diversified income streams. Continued progress in these ventures could enhance Oramed's business prospects and market presence [S2][N4][N5][N7].
Oramed faces risks including dependency on joint ventures where approval rights and differing investor interests may limit flexibility and benefits. The company is exposed to healthcare policy changes that could constrain pricing and reimbursement for its products. Currency exchange fluctuations impact costs and financial results due to operations in multiple currencies. Investments in clinical-stage companies carry inherent risks of clinical trial failures, regulatory delays, and market volatility, which could materially affect investment values. Additionally, stock price volatility and Nasdaq listing compliance pose risks to shareholder value and capital raising ability [S1][S2].
Oramed's moat is based on its proprietary oral insulin delivery technology and its strategic investments and partnerships in related medical and pharmaceutical ventures. The transfer of its POD technology to OraTech and the significant ownership stake in Lifeward provide potential for value creation through joint ventures and technology commercialization. The company's alliances with clinical-stage companies like Alpha Tau offer exposure to innovative oncology therapeutics. However, the moat is subject to risks from regulatory approvals, clinical trial outcomes, and competitive pressures in the pharmaceutical and medical device industries. The company's ability to retain key scientific personnel and manage joint venture relationships also influences its competitive position [S1].
• Joint Venture Risks: Oramed's participation in joint ventures involves shared approval rights, potential capital contributions, conflicting investor interests, and regulatory differences that may limit flexibility and benefits.
• Healthcare Policy Changes: Changes in U.S. healthcare legislation and reimbursement policies could reduce pricing and revenue potential for Oramed's products.
• Currency Exchange Exposure: Operations in multiple currencies expose Oramed to fluctuations that can adversely affect financial results.
• Investment Risks: Investments in clinical-stage companies like Alpha Tau and Scilex carry risks of clinical failure, regulatory challenges, and market volatility impacting investment value.
• Stock Price and Listing Risks: Volatility in Oramed's stock price and the need to maintain Nasdaq listing requirements pose risks to shareholder value and capital access.
Business trends: Transition of oral insulin technology to OraTech and strategic investments in clinical-stage companies shape Oramed's evolving business model.
Execution milestones: Completion of POD technology transfer, establishment of Lifeward ownership stake, and alliance formation with Alpha Tau.
Key risks: Joint venture complexities, healthcare policy changes, currency exposure, and investment risks in clinical-stage ventures.
Very high visibility
Visibility score reflects the breadth and consistency of available disclosure across SEC filings, recent public reporting, and baseline business context (research-only; not investment advice).
- Oramed Pharmaceuticals Inc. is a pharmaceutical company with a focus on oral insulin delivery and related technologies [S1][S2].
- The company transferred its POD™ technology platform activity to OraTech on March 25, 2026, and since then OraTech has conducted related research and development [S2].
- Oramed holds a 49.9% beneficial ownership interest in Lifeward, a medical device company, following a transfer of POD technology to Lifeward [N4][S2].
- Oramed has strategic alliances and investments in companies including Alpha Tau, Scilex, Hapisga, and Lifeward [S2][N5].
- Alpha Tau is a clinical-stage oncology therapeutics company; Oramed's investment value depends on Alpha Tau's clinical and regulatory success [S1].
- Oramed holds secured notes and warrants related to Scilex, with some risk of default and repayment uncertainty [S1].
- The company has recognized revenue from license agreements such as the HTIT License Agreement and Medicox License Agreement, but revenue recognition has decreased due to full recognition of deferred revenue and strategic changes [S2].
- Oramed's financials as of September 30, 2026, include cash and equivalents of approximately $15.2 million, short-term investments of $0.58 million, current assets of $57.4 million, and current liabilities of $9.4 million, resulting in a current ratio of 6.07 and a cash ratio of 1.68 [S2].
- Net income for the nine months ended September 30, 2026 was approximately $13.5 million, with basic EPS of $0.44 and diluted EPS of $0.43 [S2].
- Research and development expenses decreased significantly in 2026 due to the transfer of POD technology activities to OraTech [S2].
- General and administrative expenses increased in 2026, mainly due to higher stock-based compensation and salary expenses [S2].
- Oramed has material cash commitments including operating leases, income taxes payable, capital commitments to real estate projects, and potential additional notes related to Lifeward [S2].
- The company has experienced stock price volatility related to clinical trial results and strategic decisions [S1].
- Oramed's common stock is listed on Nasdaq Capital Market and must maintain minimum bid price requirements to avoid delisting risks [S1].
- Oramed's business is affected by risks including joint venture limitations, healthcare policy changes, currency exchange fluctuations, and investment risks in associated companies [S1].
- Recent news highlights include Oramed transferring POD technology to Lifeward, receiving a 49.9% ownership interest [N4], and forming a strategic alliance with Alpha Tau following a $36.9 million offering [N5].
- Oramed's new OraTech venture aims to revolutionize diabetes care with oral insulin delivery [N7].
- Oramed was noted among biotech stocks at 52-week highs in August 2026 [N2].
- Lifeward named Josh Hexter as interim CEO and Rami Aviram as CFO in September 2026 [N1].
Generated 2026-11-12
- S1 | 2026-03-26 | 10-K
- S2 | 2026-11-12 | 10-Q
- N1 | 2026-09-01 | www.nasdaq.com | Lifeward Names Josh Hexter Interim CEO, Rami Aviram As CFO | https://www.nasdaq.com/articles/lifeward-names-josh-hexter-interim-ceo-rami-aviram-cfo
- N2 | 2026-08-28 | www.nasdaq.com | Biotech Stocks At 52-Week Highs - NEO, BLSM, RVMD, ORMP, CADL | https://www.nasdaq.com/articles/biotech-stocks-52-week-highs-neo-blsm-rvmd-ormp-cadl
- N3 | 2026-06-26 | www.nasdaq.com | Top Biotech Gainers: TECH Bought Out, MSLE On Watch, KYMR Hits New High, What's The Buzz At SLS? | https://www.nasdaq.com/articles/top-biotech-gainers-tech-bought-out-msle-watch-kymr-hits-new-high-whats-buzz-sls
- N4 | 2026-01-13 | www.nasdaq.com | Oramed To Transfer POD Technology To Lifeward; To Receive 49.9% Beneficial Ownership Interest | https://www.nasdaq.com/articles/oramed-transfer-pod-technology-lifeward-receive-499-beneficial-ownership-interest
- N5 | 2025-04-28 | www.nasdaq.com | Alpha Tau Closes $36.9 Mln Offering And Forms Strategic Alliance With Oramed Pharmaceuticals | https://www.nasdaq.com/articles/alpha-tau-closes-369-mln-offering-and-forms-strategic-alliance-oramed-pharmaceuticals
- N6 | 2025-02-26 | www.nasdaq.com | Congress Trade: Representative Brad Knott Just Disclosed New Stock Trades | https://www.nasdaq.com/articles/congress-trade-representative-brad-knott-just-disclosed-new-stock-trades
- N7 | 2025-02-11 | www.nasdaq.com | Oramed's New OraTech Venture Aims To Revolutionize Diabetes Care With Oral Insulin Delivery | https://www.nasdaq.com/articles/orameds-new-oratech-venture-aims-revolutionize-diabetes-care-oral-insulin-delivery
- N8 | 2025-01-10 | www.nasdaq.com | Analysts Predict 14% Upside For The Holdings of DCOR | https://www.nasdaq.com/articles/analysts-predict-14-upside-holdings-dcor
This material is for informational purposes only and does not constitute investment, financial, legal or tax advice, or an offer or solicitation to buy or sell any security. The Valye AI Score is a model-based estimate derived from public information and is subject to change without notice. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information herein. Past performance is not indicative of future results. Investors should conduct their own research and consult a qualified financial adviser before making any investment decisions.

Generated by Valye SEC Pipeline Engine
.gif)


